发明名称 Dual-acting benzoimidazole antihypertensive agents
摘要 The invention is directed to compounds having the formula:; wherein: Ar, r, n, X, R2-3 and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
申请公布号 US9198899(B2) 申请公布日期 2015.12.01
申请号 US201314132391 申请日期 2013.12.18
申请人 Theravance Biopharma R&D IP, LLC 发明人 Allegretti Paul;Choi Seok-Ki;Fatheree Paul R.;Gendron Roland;Hudson Ryan;Jendza Keith;McKinnell Robert Murray;McMurtrie Darren;Olson Brooke
分类号 C07D235/08;A61K31/4184;C07D401/12;C07D403/10;C07D403/12;C07D405/12;A61K31/4439;A61K31/5377;A61K45/06;C07D405/10 主分类号 C07D235/08
代理机构 代理人 Hagenah Jeffrey A.
主权项 1. A compound of formula I: wherein: r is 0, 1 or 2;Ar is:  R1 is selected from —COOR1a, —NHSO2R1b, —SO2NHR1d, —SO2OH, —C(O)NH—SO2R1c, —P(O)(OH)2, —CN, —OCH(R1e)—COOH, tetrazol-5-yl, where R1a is H, —C1-6 alkyl, —C1-3 alkylenearyl, —C1-3 alkyleneheteroaryl, —C3-7 cycloalkyl, —CH(C1-4alkyl)OC(O)R1aa, —C0-6alkylenemorpholine, R1aa is —O—C1-6alkyl, —O—C3-7cycloalkyl, —NR1abR1ac, or —CH(NH2)CH2COOCH3; R1ab and R1ac are independently selected from H, —C1-6alkyl, and benzyl, or are taken together as —(CH2)3-6—; R1b is R1c or —NHC(O)R1c; R1c is —C1-6alkyl, —C0-6alkylene-O—R1ca, —C1-5alkylene-NR1cbR1cc, —C0-4alkylenearyl or —C0-4alkyleneheteroaryl; R1ca is H, —C1-6alkyl, or —C1-6alkylene-O—C1-6alkyl; R1cb and R1cc are independently selected from H and —C1-6alkyl, or are taken together as —(CH2)2—O—(CH2)2— or —(CH2)2—N[C(O)CH3]—(CH2)2—; R1d is H, R1c, —C(O)R1c, or —C(O)NHR1c; R1e is —C1-4alkyl or aryl; n is 0, 1, 2 or 3;each R2 is independently selected from halo, —NO2, —C1-6alkyl, —C2-6alkenyl, —C3-6cycloalkyl, —CN, —C(O)R2a, —C0-5alkylene-OR2b, —C0-5alkylene-NR2cR2d, —C0-3alkylenearyl, and —C0-3alkyleneheteroaryl; where R2a is H, —C1-6alkyl, —C3-6cycloalkyl, —OR2b, or —NR2cR2d; R2b is H, —C1-6alkyl, —C3-6cycloalkyl, or —C0-1alkylenearyl; and R2c and R2d are independently selected from H, —C1-4alkyl, and —C0-1alkylenearyl;R3 is selected from —C1-10alkyl, —C2-10alkenyl, —C3-10alkynyl, —C0-3alkylene-C3-7cycloalkyl, —C2-3alkenylene-C3-7cycloalkyl, —C2-3alkynylene-C3-7cycloalkyl, —C0-5alkylene-NR3a—C0-5alkylene-R3b, —C0-5alkylene-O—C0-5alkylene-R3b, —C0-5alkylene-S—C1-5alkylene-R3b, and —C0-3alkylenearyl; where R3a is H, —C1-6alkyl, —C3-7cycloalkyl, or —C0-3alkylenearyl; and R3b is H, —C1-6alkyl, —C3-7cycloalkyl, —C2-4alkenyl, —C2-4alkynyl, or aryl;X is —C1-12alkylene-, where at least one —CH2— moiety in the alkylene is replaced with a —NR4a—C(O)— or —C(O)—NR4a- moiety, where R4a is H, —OH, or —C1-4alkyl;R5 is selected from —C0-3alkylene-SR5a, —C0-3alkylene-C(O)NR5bR5c, —C0-3alkylene-NR5b—C(O)R5d, —NH—C0-1alkylene-P(O)(OR5e)2, —C0-3alkylene-P(O)OR5eR5f, —C0-2alkylene-CHR5g—COOH, —C0-3alkylene-C(O)NR5h—CHR5i—COOH, and —C0-3alkylene-S—SR5j; where R5a is H or —C(O)—R5aa; R5aa is —C1-6alkyl, —C0-6alkylene-C3-7cycloalkyl, -aminoC4-7cycloalkyl, —C0-6alkylenearyl, —C0-6alkyleneheteroaryl, —C0-6alkylenemorpholine, —C0-6alkylenepiperazine-CH3, —C0-6alkylenepiperidine, —C0-6alkylenepiperidine-CH3, —CH[N(R5ab)2]-aa where aa is an amino acid side chain, —C0-6alkylene-CH[N(R5ab)2]-R5ac, -2-pyrrolidine, -2-tetrahydrofuran, —C0-6alkylene-OR5ab, —O—C0-6alkylenearyl, —C1-2alkylene-OC(O)—C1-6alkyl, —C1-2alkylene-OC(O)—C0-6alkylenearyl, —O—C1-2alkylene-OC(O)O—C1-6alkyl, —C-4alkylene-COOH, or -arylene-COOH; R5ab is independently H or —C1-6alkyl; R5ac is H, —C1-6alkyl, —CH2—C3-7cycloalkyl or —COOH; R5b is H, —OH, —OC(O)R5ba, —CH2COOH, —O-benzyl, -pyridyl, or —OC(S)NR5bbR5bc; R5ba is H, —C1-6alkyl, aryl, —OCH2-aryl, —CH2O-aryl, or —NR5bbR5bc; R5bb and R5bc are independently selected from H and —C1-4alkyl; R5c is H, —C1-6alkyl, or —C(O)R5ca; R5ca is —C1-6alkyl, —C3-7cycloalkyl, aryl, or heteroaryl; R5d is H, —C1-4alkyl, —C0-3alkylenearyl, —NR5daR5db, —CH2SH, or —O—C1-6alkyl; R5da and R5db are independently selected from H and —C1-4alkyl; R5e is H, —C1-6alkyl, —C1-3alkylenearyl, —C1-3alkyleneheteroaryl, —C3-7cycloalkyl, —CH(CH3)OC(O)R5ea, R5ea is —O—C1-6alkyl, —O—C3-7cycloalkyl, —NR5ebR5ec, or —CH(NH2)CH2COOCH3; R5eb and R5ee are independently selected from H, —C1-4alkyl, and —C1-3alkylenearyl, or are taken together as —(CH2)3-6—; R5f is H, —C1-4alkyl, —C0-3alkylenearyl, —C1-3alkylene-NR5faR5fb, or —C1-3alkylene(aryl)-C0-3alkylene-NR5faR5fb; R5fa and R5fb are independently selected from H and —C1-4alkyl; R5g is H, —C1-6alkyl, —C1-3alkylenearyl, or —CH2—O—(CH2)2—OCH3; R5h is H or —C1-4alkyl; R5i is H, —C1-4alkyl, or —C0-3alkylenearyl; and R5j is —C1-6alkyl, aryl, or —CH2CH(NH2)COOH; R6 is selected from —C1-6alkyl, —CH2O(CH2)2OCH3, —C1-6alkylene-O—C1-6alkyl, —C1-3alkylenearyl, —C0-3alkyleneheteroaryl, and —C0-3alkylene-C3-7cycloalkyl; andR7 is H or is taken together with R6 to form —C3-8cycloalkyl;wherein: each —CH2— group in —(CH2)r— is optionally substituted with 1 or 2 substituents independently selected from —C1-4alkyl and fluoro;each carbon atom in the alkylene moiety in X is optionally substituted with one or more R4b groups and one —CH2— moiety in X may be replaced with a group selected from —C3-8cycloalkylene-, —CR4d═CH—, and —CH═CR4d—; where R4b is —C0-5alkylene-COOR4c, —C1-6 alkyl, —C0-1alkylene-CONH2, —C1-2 alkylene-OH, —C0-3alkylene-C3 -7 cycloalkyl, 1H-indol-3-yl, benzyl, or hydroxybenzyl; R4c is H or —C1-4alkyl; and R4d is —CH2-thiophene or phenyl;each alkyl and each aryl in R1-3, R4a-4d, and R5-6 is optionally substituted with 1 to 7 fluoro atoms;Ar and each aryl and heteroaryl in R1-3 and R5-6 is optionally substituted with 1 to 3 substituents independently selected from —OH, —C1-6alkyl, —C2-4alkenyl, —C2-4alkynyl, —CN, halo, —O—C1-6alkyl, —S—C1-6alkyl, —S(O)—C1-6alkyl, —S(O)2—C1-4alkyl, -phenyl, —NO2, —NH2, —NH—C1-6alkyl and —N(C1-6alkyl)2, wherein each alkyl, alkenyl and alkynyl is optionally substituted with 1 to 5 fluoro atoms;and pharmaceutically acceptable salts thereof.
地址 South San Francisco CA US